Tumor angiogenesis - A potential target in cancer chemoprevention

Food and Chemical Toxicology

Volumn 46, Issue 4, 2008, Pages 1334-1345

  Bhat, Tariq A ^a   Singh, Rana P ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Chemopreventive agent; Tumor angiogenesis; Vascular endothelial growth factor

Indexed keywords

3' HYDROXYFLAVONE; 3',4' DIHYDROXYFLAVONE; APIGENIN; CHRYSOBALANUS ICACO EXTRACT; CONJUGATED LINOLEIC ACID; CURCUMIN; EFLORNITHINE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; FISETIN; FLAVOPIRIDOL; GENISTEIN; GREEN TEA EXTRACT; ISOLIQUIRITIGENIN; ISOTHIOCYANIC ACID; LUTEOLIN; PHENETHYL ISOTHIOCYANATE; PHENYL ISOTHIOCYANATE; PHILINOPSIDE A; PLANT EXTRACT; QUERCETIN; RESVERATROL; RETINOIC ACID; ROQUINIMEX; SELENIUM; SILIBININ; SILYMARIN; SULFORAPHANE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ARTICLE; CELL GROWTH; CELL MIGRATION; CHEMOPROPHYLAXIS; DIET; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; MEDICAL RESEARCH; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CYTOKINES; DIET; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION;

EID: 39149110961     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2007.08.032     Document Type: Article

References (123)

1. Abdollahi A., Griggs D.W., Zieher H., Roth A., Lipson K.E., Saffrich R., Grone H.J., Hallahan D.E., Reisfeld R.A., Debus J., Niethammer A.J., and Huber P.E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 11 (2005) 6270-6279
2. Adhami V.M., Siddiqui I.A., Ahmad N., Gupta S., and Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 64 (2004) 8715-8722
3. Ahmad N., Gali H., Javed S., and Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem. Biophys. Res. Commun. 248 (1998) 294-301
4. Ahmad N., Gupta S., and Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κ-B in cancer cells versus normal cells. Arch. Biochem. Biophys. 376 (2000) 338-346
5. Aronen H.J., Pardo F.S., Kennedy D.N., Belliveau J.W., Packard S.D., Hsu D.W., Hochberg F.H., Fischman A.J., and Rosen B.R. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin. Cancer Res. 6 (2000) 2189-2200
6. Bancroft C.C., Chen Z., Yeh J., Sunwoo J.B., Yeh N.T., Jackson S., Jackson C., and Van Wates C. Effects of pharmacologic antagonists of epidermal growth factor receptor, pi3k and mek signal kinases on nf-κb and ap1 activation and il-8 and vegf expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer 99 (2002) 538-548
7. Banerjee S., Bueso-Ramos C., and Aggarwal B.B. Suppression of 7,12-dimethylbenzanthrace-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-(B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62 (2002) 4945-4954
8. Belvisi L., Riccioni T., Marcellini M., Vesci L., Chiarucci I., Efrati D., Potenza D., Scolastico C., Manzoni L., Lombardo K., Stasi M.A., Orlandi A., Ciucci A., Nico B., Ribatti D., Giannini G., Presta M., Carminati P., and Pisano C. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol. Cancer Ther. 4 (2005) 1670-1680
9. Bertl E., Bartsch H., and Gerhauser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol. Cancer Ther. 5 (2006) 575-585
10. Binder B.R., Mihaly J., and Prager G.W. uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view. Thromb. Haemostasis 97 (2007) 336-342
11. Boehm T., Folkman J., Browder T., and O'Really M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
12. Brekken R.A., Li C., and Kumar S. Strategies for vascular targeting in tumors. Int. J. Cancer 100 (2002) 123-130
13. Cai T., Fassina G., Morini M., Aluigi M.G., Masiello L., Fontanini G., D'Agostini F., De Flora S., Noonan D.M., and Albini A. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 79 (1999) 1151-1159
14. Cao Y., Cao R., and Brakenheilm E. Antiangiogenic mechanisms of diet-derived polyphenols. J. Nutr. Biochem. 13 (2002) 380-390
15. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2002) 389-395
16. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
17. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nat. Med. 407 (2000) 249-257
18. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Henneken C.H., and Pollak M. Plasma insulin-like growth factor-i and prostate cancer risk: a prospective study. Science (Washington, DC) 279 (1998) 563-566
19. Chen P.N., Kuo W.H., Chiang C.L., Chiou H.L., Hsieh Y.S., and Chu S.C. Black rice anthocyanins inhibit cancer cells invasion via repressions of MMPs and u-PA expression. Chem. Biol. Interact. 163 (2006) 218-229
20. Chu S.C., Chiou H.L., Chen P.N., Yang S.F., and Hsieh Y.S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinogen. 40 (2004) 143-149
21. Clinton S.K., and Giovannucci E. Diet, nutrition, and prostate cancer. Ann. Rev. Nutr. 18 (1998) 413-440
22. Clinton S.K., Palmer S.S., Spriggs C.E., and Visek W.J. The growth of dunning transplantable prostate adenocarcinomas in rats fed with various fat contents. J. Nutr. 118 (1988) 908-914
23. Dell'eva R., Ambrosini C., Minghelli S., Noonan D.M., Albini A., and Ferrari N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{κ}B pathway. Carcinogenesis 28 (2007) 404-413
24. Dhanalakshmi S., Singh R.P., Agarwal C., and Agarwal R. Silibinin inhibits constitutive and TNFα-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis. Oncogene 21 (2002) 1759-1767
25. Di G.H., Li H.C., Shen Z.Z., and Shao Z.M. Analysis of anti-proliferation of curcumin on human breast cancer cells and its mechanism. Zhonghua Yi Xue Za Zhi 83 (2003) 1764-1768
26. Dorai T., and Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett. 215 (2004) 129-140
27. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., and Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 61 (2001) 2145-2153
28. Fang J., Zhou Q., Liu L.Z., Xia C., Hu X., Shi X., and Jiang B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1{alpha} and VEGF expression. Carcinogenesis (2006) (Epub ahead of print)
29. Fassina G., Vene R., Morini M., Minghelli S., Benelli R., Noonan D.M., and Albini A. Mechanism of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res. 10 (2004) 4865-4873
30. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 11 (2000) 617-624
31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2 (2002) 795-803
32. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
33. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133 (1971) 275-288
34. Fotsis T., Pepper M.S., Aktas E., Breit S., Rasku S., Adlercreutz H., Wahala K., Montesano R., and Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 57 (1997) 2916-2921
35. Fu X.S., Choi E., Bubley G.J., and Balk S.P. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63 (2005) 215-221
36. Gimbrone Jr. M.A., Leapman S., Cotran R., and Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136 (1972) 261-276
37. Gupta R.A., and Dubois R.N. Combinations for chemoprevention. Nat. Med. 6 (2000) 974-975
38. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
39. Harris A.L. Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2 (2002) 38-47
40. Helenius M.A., Saramaki O.R., Linja M.J., Tammela T.L., and Visakorpi T. Amplification of urokinase gene in prostate cancer. Cancer Res. 61 (2001) 5340-5344
41. Holmes-Mcnary M., and Baldwin Jr. A.S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the iκb kinase. Cancer Res. 60 (2000) 3477-3483
42. Hong J.H., Ahn K.S., Bae E., Jeon S.S., and Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 9 (2006) 147-152
43. Hong W.K., and Sporn M.B. Recent advances in chemoprevention of cancer. Science 278 (1997) 1073-1077
44. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
45. Huang S., Robinson J.B., Deguzman A., Bucana C.D., and Fidler I.J. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenecity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60 (2000) 5334-5339
46. Huang Y.T., Hwang J.J., Lee P.P., Ke F.C., Huang J.H., Kandaswami C., Middleton Jr. E., and Lee M.T. Effects of luteolin and quercetin, inhibitors of tyrosin kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Brit. J. Pharmacol. 128 (1999) 999-1010
47. Ishii K., Usui S., Sugimura Y., Yamamoto H., Yoshikawa K., and Hiran K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol. Pharmaceut. Bull. 24 (2001) 188-190
48. Jiang C., Agarwal R., and Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem. Biophys. Res. Commun. 276 (2000) 371-378
49. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
50. Joseph I.B., Vukanovik J., and Issaca J.T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 56 (1996) 3404-3408
51. Jung Y.D., Kim M.S., Shin B.A., Chay K.O., Ahn B.W., Liu W., Bucana C.D., Gallick G.E., and Ellis L.M. EGCG, a major component of green tea, inhibits tumor growth by inhibiting vegf induction in human colon carcinoma cells. Brit. J. Cancer 84 (2001) 844-850
52. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
53. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22 (2004) 4991-5004
54. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362 (1993) 841-844
55. Kim M.S., Lee Y.M., Moon E.J., Kim S.E., Lee J.J., and Kim K.W. Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Int. J. Cancer 87 (2000) 269-275
56. Klein E.A. Chemoprevention of prostate cancer. Ann. Rev. Med. 57 (2006) 49-63
57. Lee E.O., Lee H.J., Hawang H.S., Ahn K.S., Chae C., Kang K.S., Lu J., and Kim S.H. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 27 (2006) 2059-2069
58. Lee H.J., Lee H.J., Song G.Y., Li G., Lee J.H., Lu J., and Kim S.H. 6-(1-Oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits Lewis lung cancer by antiangiogenesis and apotosis. Int. J. Cancer (2007) (EPUB ahead of print)
59. Lee H.J., Leo E.O., Rhee Y.H., Ahn K.S., Li G.X., Jiang C., Lu J., and Kim S.H. An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis 27 (2006) 2455-2463
60. Li Y., and Sarkar F.H. Inhibition of nuclear factor-κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8 (2002) 2369-2377
61. Lin Y.L., and Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB. Mol. Pharmacol. 52 (1997) 465-472
62. Liotta L.A., and Kohn E.C. The microenvironment of the tumor-host interface. Nature 411 (2001) 375-379
63. Lippman S.M., and Hong W.K. Cancer prevention science and practice. Cancer Res. 62 (2002) 5119-5125
64. Lloyd F.P.Jr., Slivova V., Valachovicova T., and Sliva D. Aspirin inhibits highly invasive prostate cancer cells. Int. J. Oncol. 23 (2003) 1277-1283
65. Lopez-Lazaro M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol. Biomar. Prev. 15 (2006) 2332-2335
66. Mabjeesh N.J., Willard M.T., Frederickson C.E., Zhong H., and Simons J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 9 (2003) 2416-2425
67. Madge L.A., and Peber J.S. A phosphatidylinositol 3-kinase/akt pathway, activated by tumor necrosis factory or interleukin-1, inhibits apoptosis but does not activate NF-κB in human endothelial cells. J. Biol. Chem. 275 (2000) 15458-15465
68. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 (2000) 1306-1311
69. Masso-Welch B.A., Zangani D., Clement Ip., Vaughan M.M., Shoemaker S.F., McGee S.O., and Margot M.Ip. Isomers of conjugated linoleic acid differ in their effects on angiogenesis and survival of mouse mammary adipose vasculature. J. Nutr. 134 (2004) 299-307
70. Masso-Welch P.A., Zangani D., Ip C., Vaughan M.M., Shoemaker S.F., Ramirez R.A., and Ip M.M. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res. 62 (2002) 4383-4389
71. Mehta P.B., Jenkins B.L., McCarthy L., Thilak L., Robson C.N., Neal D.E., and Leung H.Y. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22 (2003) 1381-1389
72. Mukherjee P., El-Abbadi M.M., Kasperzyk J.L., Ranes M.K., and Seyfried T.N. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Brit. J. Cancer 86 (2002) 1615-1621
73. Mukherjee P., Sotnikov A.V., Mangian H.J., Zhou J.R., Visek W.J., and Clinton S.K. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 91 (1999) 512-523
74. Mutoh M., Takahashi M., Fukuda K., Matsushima-Hibiya Y., Mutoh H., Sugimura T., and Wakabayashi K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21 (2000) 959-963
75. Neto C.C. Cranberry and its phytochemicals: a review of in vitro anticancer studies. J. Nutr. 137 (2007) 186S-193S
76. Nomura M., Ma W., Chen N., Bode A.M., and Dong Z. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-κB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 21 (2000) 1885-1890
77. Nor J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of bcl-2 expression. Am. J. Pathol. 154 (1999) 375-384
78. Ono M., Torisu H., Fukushi J., Nishie A., and Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 43 (1999) 69S-71S
79. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2 (2002) 657-672
80. Paper D.H. Natural products as angiogenesis inhibitors. Planta Med. 64 (1998) 686-695
81. Peng P.L., Hsieh Y.S., Wang C.J., Hsu J.L., and Chou F.P. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol. Appl. Pharmacol. 214 (2006) 8-15
82. Pezzato E., Sartor L., Dell'Aica I., Dittadi R., Gion M., Belluco C., Lise M., and Garbisa S. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)-epigallocatechin-3-gallate. Int. J. Cancer 112 (2004) 787-792
83. Pugh C.W., and Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 13 (2003) 83-89
84. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., and Rao J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280 (2005) 36529-36540
85. Rapella A., Negrioli A., Melillo G., Pastorino S., Varesio L., and Bosco M.C. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int. J. Cancer 99 (2002) 658-664
86. Rose D.P., and Connolly J.M. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18 (1991) 243-254
87. Rose D.P., and Connolly J.M. Regulation of tumor angiogenesis by dietary fatty acids and eicosnoids. Nutr. Cancer 37 (2000) 119-127
88. Sartor L., Pezzato E., Dona M., Dell'Aica I., Calabrese F., Morini M., Albini A., and Garbisa S. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int. J. Cancer 112 (2004) 823-829
89. Shao Z.M., Wu J., Shen Z.Z., and Barsky S.H. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 58 (1998) 4851-4857
90. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metast. Rev. 20 (2001) 287-296
91. Shih S.C., and Claffey K.P. Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 19 (2001) 19-34
92. Singh D.K., and Lippman S.M. Cancer chemoprevention part 2: hormones, nonclassic antioxidant natural agents, NSAIDS, and other agents. Oncology 12 (1998) 1787-1800
93. Singh R.P., and Agarwal R. Tumor angiogenesis - a potential target in cancer control by phytochemicals. Curr. Cancer Drug Targets 3 (2003) 203-215
94. Singh S., and Aggarwal B.B. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270 (1995) 24995-25000
95. Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy. Oncogene 24 (2005) 1188-1202
96. Skogseth H., Larsson E., and Halgunset J. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells. Acta Patholo. Microbiol. et Immunol. Scand. 113 (2005) 332-339
97. Slack-Davis J.K., and Parsons J.T. Emerging views of integrin signaling: implications for prostate cancer. J. Cell. Biochem. 91 (2004) 41-46
98. Sporn M.B., and Suh N. Chemoprevention of cancer. Carcinogenesis 21 (2000) 525-530
99. Surh Y.J. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem. Toxicol. 40 (2002) 1091-1097
100. Surh Y.J., Na H.K., Lee J.Y., and Keum Y.S. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed panax ginseng C. A. Meyer. J. Korean Med. Sci. 16 (2001) 38S-41S
101. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keu Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res. 480-481 (2001) 243-268
102. Takaha N., Resar L.M., Vindivich D., and Coffey D.S. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 60 (2004) 160-167
103. Takahashi T., Ueno H., and Shibuya M. VEGF activates protein kinase c-dependent, but ras-independent raf-mek-map kinase pathway for dna synthesis in primary endothelial cells. Oncogene 18 (1999) 2221-2230
104. Tang F.Y., Chiang E.P., and Schih C.J. Green tea catechin inhibits ephrin-A1mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J. Nutr. Biochem. (2006) (EPUB ahead of print)
105. Thurston G., Suri C., Smith K., Mcclain J., Sato T.N., Yancopoulos G.D., and Mcdonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999) 2511-2514
106. Tosetti F., Ferrari N., Deflora S., and Albini A. 'Angioprevention': angiogenesis is a common key target for cancer chemopreventive agents. FASEB J. 16 (2002) 2-14
107. Tsai S.H., Liang Y.C., Lin-Shiau S.Y., and Lin J.K. Suppression of TNFα-mediated NF-κB activity by myricetin and other flavonoids through down regulating the activity of IKK in ECV304 cells. J. Cell Biochem. 74 (1999) 606-615
108. Tsubono Y., Nishino Y., Komatsu S., Hseih C.C., Kanemura S., Tsuji I., Nakatsuka H., Fukao A., Satoh H., and Hisamichi S. Green tea and the risk of gastric cancer in Japan. N. Engl. J. Med. 344 (2001) 632-636
109. Turner H.E., Harris A.L., Melmed S., and Wass J.A. Angiogenesis in endocrine tumors. Endocr. Rev. 24 (2003) 600-632
110. Vucenik I., Passaniti A., Vitolo M.I., Tantivejkul K., Eggleton P., and Shamsuddin A.M. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 25 (2004) 2115-2123
111. Wang Y., Corr J.G., Thaler H.T., Tao Y., Fair W.R., and Heston W.D. Decreased growth of established human prostate lncap tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 87 (1995) 1456-1462
112. Webber M.M., and Waghray A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin. Cancer Res. 1 (1995) 755-761
113. Whittemore A.S., Kolonel L.N., Wu A.H., John E.M., Gallagher R.P., Howe G.R., Burch J.D., Hankin J., Dreon D.M., and West D.W. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl. Cancer Inst. 87 (1995) 652-661
114. Xiao D., and Singh S.V. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res. 67 (2007) 2239-2246
115. Xu C., Shen G., Chen C., Gelinas C., and Kong A.N. Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBalpha, IKK pathway in human prostate cancer PC3 cells. Oncogene 24 (2005) 4486-4495
116. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., and Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol. Cell Biol. 17 (1997) 4015-4023
117. 2 and the angiotensis-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol. 42 (2005) 687-693
118. Yu G.P., Hsieh C.C., Wang L.Y., Yu S.Z., Li X.L., and Jin T.H. Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. Cancer Causes Control 6 (1995) 532-538
119. Zhao J., Sharma Y., and Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-otetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1α expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol. Carcinogen. 26 (1999) 321-333
120. Zhen M.C., Huang X.H., Wang Q., Sun K., Liu Y.J., Li W., Zhang L.J., Cao L.Q., and Chen X.L. Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol. Sinic. 27 (2006) 1600-1607
121. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., and Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 129 (1999) 1628-1635
122. Zi X., and Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem. Biophys. Res. Commun. 263 (1999) 528-536
123. Zi X., Grasso A.W., Kung H., and Agarwal R.A. A flavonoid antioxidant, silymarin, inhibits activation of ErbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 58 (1998) 1920-1929